This is an exciting news from the world of medical research!
In a remarkable development in the field of medical science, a recent Phase II clinical study has brought new hope to patients suffering from Ataxia Telangiectasia (AT), a rare neurodegenerative disorder. This study, involving ChromaDex’s patented nicotinamide riboside (NR) ingredient, Niagen®, has shown promising results in improving the lives of those affected by AT.
Understanding Ataxia Telangiectasia (AT)
Before diving into the study, let’s understand what AT is.
What is Ataxia Telangiectasia?
Ataxia Telangiectasia (AT) is a rare inherited disorder that affects the nervous system, immune system, and other body systems. It is also known as Louis-Bar syndrome, cerebello-oculocutaneous telangiectasia, or immunodeficiency with ataxia telangiectasia. The condition usually begins in early childhood, before the age of 5, and is caused by mutations in the ATM (ataxia-telangiectasis mutated) gene.
How it affects the body?
AT affects the part of the brain that controls motor movement and speech, as well as the spine and immune system. Common symptoms include unsteady walking, lack of balance, lack of coordination of movement, slurred speech, difficulty swallowing, unintentional movement, tremors, and difficulty coordinating eye movement. Other symptoms may include frequent respiratory infections, red “spider” veins around the eyes, ears, or cheeks (telangiectasias), increased sensitivity to ionizing radiation, diabetes, premature graying of the hair, fatigue, and delayed physical and sexual development.
People with AT often have a weakened immune system and an increased risk of developing cancer, particularly leukemia and lymphoma. They are also very sensitive to the effects of radiation exposure, including medical x-rays.
What are the treatments?
While there is no cure for AT, treatments such as physical and speech therapy, and improving deficits in the immune system and nutrition, might help improve some symptoms. The life expectancy of individuals with AT varies greatly but affected individuals typically live into early adulthood.
Clinical trials are being conducted to learn more about AT and related disorders, and individuals with AT or their loved ones are encouraged to consider participating in these trials to contribute to the advancement of knowledge and potential treatments for the condition.
In summary, AT is a genetic condition characterized by progressive neurological problems, weakened immune systems, and a higher risk of cancer. Patients with AT often experience difficulties with motor coordination and eye movements, significantly impacting their daily lives.
The Role of Niagen® in AT Treatment
Niagen® (NR), a form of nicotinamide riboside, has emerged as a beacon of hope. It is a form of vitamin B3 that plays a crucial role in the body’s production of nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in various biological processes. Research has shown that NR supplementation can have potential therapeutic uses in various health conditions, including its role in the NAD+ biosynthetic pathway and its protective effects in adverse cardiac remodeling.
NAD+ is involved in various cellular processes, including DNA repair, energy metabolism, and maintaining the health of mitochondria. Given that AT affects multiple body systems, including the nervous system and immune system, supporting cellular health through NAD+ production could be an area of interest for further research.
The current study, conducted over two years, involved 10 AT patients who were given oral NR starting at 150 mg/day, eventually increasing to 500 mg/day. The results were nothing short of groundbreaking.
Key Findings of the This Study
- Increased NAD+ Levels: The supplementation with Niagen® effectively increased whole blood NAD+ levels up to fourfold. NAD+ is a crucial cellular coenzyme vital for mitochondrial function, DNA repair, and cellular energy production. In AT patients, DNA damage leads to depleted NAD+, exacerbating their condition. By boosting NAD+ levels, Niagen® helps counteract this depletion.
- Improved Motor Coordination and Eye Movement: The study showed significant improvements in motor coordination and eye movement in both adult and child patients. This improvement is a major stride in enhancing the quality of life for AT patients.
- Safety and Tolerance: Importantly, the long-term supplementation of Niagen® was found to be safe and well-tolerated, with stable biomarkers for liver and kidney function.
The results of this Phase II clinical study are a beacon of hope for AT patients and their families. By increasing NAD+ levels and improving motor functions, Niagen® is paving the way for better management of this challenging condition.
ChromaDex: At the Forefront of Healthy Aging Research
ChromaDex Corp., the innovator behind Niagen®, is a global bioscience company dedicated to healthy aging. Their commitment to exploring the therapeutic effects of Niagen® in AT patients is a testament to their dedication to advancing medical science.
While these findings are indeed promising, it’s important to note that they are forward-looking statements. The impact of Niagen® on AT patients is a significant step, but like all scientific research, it requires ongoing study and validation.
As we look forward to more research in this area, we remain hopeful about the potential of Niagen® in contributing to the well-being of those affected by Ataxia Telangiectasia.